Scientists find unique nuclear DNA structure

May 14, 2000

Shed Light on Antibody Production

For the first time since Watson and Crick described the double helix, a new and unique stable nuclear DNA structure has been discovered and described by scientists at the Keck School of Medicine of the University of Southern California and the USC/Norris Comprehensive Cancer Center.

That unique DNA structure helped the scientists also elucidate for the first time the process by which the different classes of immunoglobulins (also known as antibodies) are produced.

These findings, published in the May 12 issue of the journal Science, may also help researchers better understand how one type of B cell cancer, Burkitt's lymphoma, comes into being. (The B cells are the cells that produce immunoglobulins.)

"The way in which the different immunoglobulin classes are created is a nearly perfect system," noted Michael Lieber, M.D., Ph.D., professor of pathology and biochemistry, and the study's principal investigator. "And yet, the DNA mechanism for how a cell switches from producing one class to producing another has remained a mystery for almost 20 years."

Until now, that is.

"We've discovered that it occurs by forming an unusual structure in the DNA within a chromosome," Lieber said.

Two other unusual structures have been previously described, he explained, but these are short bits of DNA that require other proteins to stabilize them. The structures being described in the Science article are long regions of DNA, and they are intrinsically stable; they don't require any outside proteins to hold them together.

The typical antibody molecule is shaped like the letter Y. The region at the end of each of the two short protein arms houses the receptors that recognize and bind with a specific foreign object, or antigen, while the long stem, or handle, determines to which immunoglobulin class the antibody belongs.

An immunoglobulin's class is important because it determines where in the body the antibody's efforts will be concentrated. And so, while immunoglobulin M (IgM) works mostly in the bloodstream, IgG, for instance, can easily slip through a capillary's walls and cross a placenta, and IgA is at home in the lungs, the digestive tract and the body's secretions - saliva, sweat and tears.

Switching from one class to another requires a change in the immunoglobulin's "handle." By undergoing this so-called class switch, the body can send "the same antibody missile to different areas of the body," Lieber explained.

By studying the process of class switching in B cells from a mouse's spleen, Lieber and Keck colleagues Robert B. Tracy, Ph.D., research associate in pathology, and Chih-Lin Hsieh, Ph.D., associate professor of urology and biochemistry and molecular biology, found that class switching involves a cutting and joining process in which the RNA strand decoding the DNA instructions "gets stuck between two strands of DNA, creating what is called an R loop," Lieber said. "These layers look a bit like a sandwich." (Tracy and Lieber described the precise structure of this R-loop in the March 1 issue of the EMBO Journal.)

That circular sandwich is transient. Eventually, the loop is snipped off and set aside, while the ends of the two remaining strands are rejoined. But the effects are long-lasting. This cutting and pasting - known as a recombination event - cannot be undone. Once a cell decides to make, for example, IgA, it must clip out the instructions for IgE, IgG and IgM. Afterwards, it can make nothing but IgA.

"In general, DNA is a stable blueprint," said Lieber. "Class switching is one of only two processes that alter the DNA blueprint in the nucleus - one of only two DNA-cutting and - joining processes in all animal cells." The other nuclear recombination event is closely related - the process that creates the antigen-binding pockets topping the short arms of the immunoglobulins.]

"We've identified a structure integral to part of the immune system, and we've detailed how it develops," said Tracy, the paper's lead author.

Now, he added, the next step is to try to tease out the nuclear enzyme, or nuclease, that actually does the cutting of the unique looped structure.

"Finding that will be critical for a detailed understanding of the whole mechanism," he said.

A detailed understanding of this immunologic mystery may also provide clues to just how Burkitt's lymphoma, a type of non-Hodgkin's lymphoma, gets its start in the human body.

It turns out, Tracy said, that when immunoglobulin class switching does not occur correctly, it can set off a chain of events that can lead to a swapping of genetic material between two chromosomes - the one containing the class-switching genes and the one on which a known cancer-causing gene resides. That translocation, as it's called, can activate the cancer-causing gene, prompting unchecked cellular division.

"If we can figure out how class switching normally works," says Tracy, "we can also begin to figure out why this cancer occurs."
-end-
The USC research was supported by National Institutes of Health grants and a Bank of America fellowship.

EDITOR: See Robert B. Tracy, Chih-Lin Hsieh, Michael R. Lieber, "Stable RNA/DNA Hybrids in the Mammalian Genome: Inducible Intermediates for Immunoglobulin Switch Recombination" in Science, 12 May 2000.

University of Southern California

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.